OncLive TV

Benjamin P. Levy, MD, discusses the importance of testing for KRAS mutations in lung cancer.

Thomas G. Martin, MD, discusses factors that can inform transplant eligibility in multiple myeloma.

Riad Salem, MD, discusses the FDA approval of TheraSphere™ Yttrium-90 Glass Microsphere in March 2021 for the treatment of patients with hepatocellular carcinoma.

Alexander Spira, MD, PhD, FACP, discusses the role of broad molecular testing in lung cancer.

Brian Till, MD, discusses the potential durability of brexucabtagene autoleucel in mantle cell lymphoma.

Michael B. Atkins, MD, discusses the FDA approval of tivozanib in relapsed/refractory advanced renal cell carcinoma.

Thomas G. Martin, MD, discusses the utility of aggressive frontline treatment in multiple myeloma.

Andre Goy, MD, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma.

Shaji K. Kumar, MD, discusses the challenges of selecting therapy for patients with heavily pretreated multiple myeloma.

Monica D. Mead, MD, discusses the role of BTK inhibition after venetoclax in relapsed/refractory chronic lymphocytic leukemia.

Tony Philip, MD, discusses advances made in the treatment of patients with colorectal cancer.

Syed Kazmi, MD, discusses choosing among regorafenib and TAS-102 in the treatment of patients with metastatic colorectal cancer.

R. Gregory Bociek, MD, discusses the role of minimal residual disease in patients with chronic lymphocytic leukemia.

Lewis Au, MBBS, BMedSci, FRACP, discusses the rationale to evaluate antiviral immunity from COVID-19 among patients with cancer.

Paul G. Richardson, MD, discusses the toxicity profile of melphalan flufenamide in relapsed/refractory multiple myeloma.

Peter Martin, MD, discusses the importance of developing novel therapies in mantle cell lymphoma.

Atrayee Basu-Mallick, MD, discusses factors to consider when selecting a frontline HER2-directed treatment regimen for patients with colorectal cancer.

John Longshore, PhD, FACMG, discusses key molecular markers in metastatic lung cancer.

Theresa Boyle, MD, PhD, discusses the role of concurrent molecular testing in lung cancer.

Andre Goy, MD, discusses the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma, as demonstrated in the phase 2 ZUMA-2 trial.

Anjana Pillai, MD, discusses the importance of multidisciplinary discussion in hepatocellular carcinoma.

Sattva Neelapu, MD, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.

Saad Z. Usmani, MD, FACP, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.

Tony Philip, MD, discusses the emerging role of circulating tumor DNA in colorectal cancer.

Patrick Borgen, MD, discusses treatment strategies for patients with male breast cancer.

Axel Grothey, MD, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer.

Monica D. Mead, MD, discusses the utility of venetoclax in combination with rituximab in the second-line setting for patients with chronic lymphocytic leukemia.

Amy Jones, MD, discusses factors that can inform frontline treatment selection in pancreatic cancer.

Peter Martin, MD, discusses the potential role of LOXO-305 in mantle cell lymphoma.

Brian Till, MD, discusses the potential to utilize CAR T-cell therapy earlier in the treatment of patients with mantle cell lymphoma.